Gabapentin enacarbil in Japanese patients with restless legs syndrome: A 12-week, randomized, double-blind, placebo-controlled, parallel-group study

Current Medical Research and Opinion

Volumn 29, Issue 1, 2013, Pages 13-21

  Inoue, Yuichi ^a,b,c   Hirata, Koichi ^d   Uchimura, Naohisa ^e   Kuroda, Kenji ^f   Hattori, Nobutaka ^g   Takeuchi, Masahiro ^h  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NEUROPSYCHIATRIC RESEARCH INSTITUTE   (Japan)

^c Yoyogi Sleep Disorder Center   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e KURUME UNIVERSITY   (Japan)

^f Hannan Hospital   (Japan)

^g JUNTENDO UNIVERSITY   (Japan)

^h KITASATO UNIVERSITY   (Japan)

Author keywords

Gabapentin enacarbil; International Restless Legs Syndrome Rating Scale; Japan; Restless Legs Syndrome; Tolerability

Indexed keywords

CLONAZEPAM; GABAPENTIN; GABAPENTIN ENACARBIL; PLACEBO; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PHOSPHOKINASE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; JAPAN; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME;

EID: 84871389240     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.746217     Document Type: Article

References (41)

1. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-54
2. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006;7:545-52
3. Nomura T, Inoue Y, Kusumi M, et al. Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord 2008;23:2363-9
4. Nomura T, Inoue Y, Kusumi M, et al. Email-based epidemiological surveys on restless legs syndrome in Japan. Sleep Biol Rhythm 2008;6:139-45
5. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92
6. Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007;16:617-24
7. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 2000;54:1064-8
8. Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 2011;11:28
9. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916-22
10. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302
11. García-Borreguero D, Hogl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 2012;27:277-83
12. Silver N, Allen RP, Senerth J, et al. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440-4
13. Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 2011;12:431-9
14. Hogl B, Garcia-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010;257:230-7
15. Ondo W, Romanyshyn J, Vuong KD, et al. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004;61:1393-7
16. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14
17. Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011;3:CD006009
18. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-9
19. Happe S, Sauter C, Klosch G, et al. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003;48:82-6
20. Gidal BE, Radulovic LL, Kruger S, et al. Inter-And intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000;40:123-7
21. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(+/-)-1-([(a- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004;311:315-23
22. Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+/-)-1-([(a- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004;311:324-33
23. Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008;48:1378-88
24. Lal R, Sukbuntherng J, Luo W, et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 2009;31:1776-86
25. Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol 2010;69:498-507
26. Lal R, Sukbuntherng J, Luo W, et al. The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. Int J Clin Pharmacol Ther 2010;48:120-8
27. Bogan RK, Bornemann MA, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 2010;85:512-21
28. Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol 2011;34:8-16
29. Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-46
30. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159-68
31. Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009;32:311-20
32. Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011;7:282-92
33. Williams DA. A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 1971;27:103-17
34. Williams DA. The comparison of several dose levels with a zero dose control. Biometrics 1972;28:519-31
35. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipex-ole in restless legs syndrome. Neurology 2006;67:1034-9
36. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
37. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine trans-dermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39
38. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-Analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008;131:902-17
39. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
40. Siddiqui O, Hung HMJ, O'Neill Robert. MMRM vs. LOCF: A comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009;19:227-246
41. Winkelman JW, Bogan RK, Schmidt MH, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011;26:2065-72